Design Therapeutics (DSGN) Proxy filing summary

Voting matters and shareholder proposals

• Election of one Class II director nominee, Simeon George, M.D., for a three-year term ending at the 2029 annual meeting.

• Ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.

Board of directors and corporate governance

• Board recommends voting FOR both the director nominee and the auditor ratification proposals.

Audit committee and external auditor matters

• Audit Committee selected Ernst & Young LLP as the independent auditor for the upcoming fiscal year.